367 related articles for article (PubMed ID: 29576279)
1. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
[TBL] [Abstract][Full Text] [Related]
2. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
[TBL] [Abstract][Full Text] [Related]
3. Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors.
Cherenfant J; Talamonti MS; Hall CR; Thurow TA; Gage MK; Stocker SJ; Lapin B; Wang E; Silverstein JC; Mangold K; Odeleye M; Kaul KL; Lamzabi I; Gattuso P; Winchester DJ; Marsh RW; Roggin KK; Bentrem DJ; Baker MS; Prinz RA
Surgery; 2014 Dec; 156(6):1504-10; discussion 1510-1. PubMed ID: 25456943
[TBL] [Abstract][Full Text] [Related]
4. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
[TBL] [Abstract][Full Text] [Related]
5. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
6. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
[TBL] [Abstract][Full Text] [Related]
7. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
[TBL] [Abstract][Full Text] [Related]
8. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.
Bilimoria KY; Talamonti MS; Tomlinson JS; Stewart AK; Winchester DP; Ko CY; Bentrem DJ
Ann Surg; 2008 Mar; 247(3):490-500. PubMed ID: 18376195
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center.
Han X; Xu X; Jin D; Wang D; Ji Y; Lou W
Pancreas; 2014 May; 43(4):526-31. PubMed ID: 24658317
[TBL] [Abstract][Full Text] [Related]
10. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
[TBL] [Abstract][Full Text] [Related]
12. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
[TBL] [Abstract][Full Text] [Related]
13. A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio.
Dasari BV; Roberts KJ; Hodson J; Stevens L; Smith AM; Hubscher SG; Isaac J; Muiesan P; Sutcliffe RP; Marudanayagam R; Mirza DF
HPB (Oxford); 2016 Apr; 18(4):332-8. PubMed ID: 27037202
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
15. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems.
Luo G; Javed A; Strosberg JR; Jin K; Zhang Y; Liu C; Xu J; Soares K; Weiss MJ; Zheng L; Wolfgang CL; Cives M; Wong J; Wang W; Sun J; Shao C; Wang W; Tan H; Li J; Ni Q; Shen L; Chen M; He J; Chen J; Yu X
J Clin Oncol; 2017 Jan; 35(3):274-280. PubMed ID: 27646952
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.
Hasegawa T; Yamao K; Hijioka S; Bhatia V; Mizuno N; Hara K; Imaoka H; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Kinoshita T; Kohsaki T; Nishimori I; Iwasaki S; Saibara T; Hosoda W; Yatabe Y
Endoscopy; 2014 Jan; 46(1):32-8. PubMed ID: 24218309
[TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.
Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T
Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945
[TBL] [Abstract][Full Text] [Related]
18. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.
Liu TC; Hamilton N; Hawkins W; Gao F; Cao D
Am J Surg Pathol; 2013 Jun; 37(6):853-9. PubMed ID: 23598967
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
20. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).
Hashim YM; Trinkaus KM; Linehan DC; Strasberg SS; Fields RC; Cao D; Hawkins WG
Ann Surg; 2014 Feb; 259(2):197-203. PubMed ID: 24253141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]